A flowering plant of variegated components and psychoactive qualities, Cannabis has lengthy been employed for medicinal and recreational purposes. Regulatory approvals have been gained across a broad variety of palliative and therapeutic indications, and in some situations, integrated in standard therapy guidelines. Locations covered: The use of Cannabis and cannabinoid-primarily based-medicines in oncology is summarized in this report. Cannabinoids are classified according to organic and synthetic subtypes and their mechanisms of action expounded. The variability of out there merchandise is discussed in the clinical context and information with regards to chemotherapy-induced nausea and vomiting, cancer-connected discomfort, anorexia, insomnia, and anxiousness are presented. Additionally, immunological and antineoplastic effects in preclinical and clinical trials are addressed. Ideas such as synergism or opposition with conventional therapy modalities, the sequence of administration and dosage, molecular cross-speak and malignancy-cannabinoid congruence, are explored. Lastly, side-effects, limitations in trial design and style and legislation barriers are connected. Specialist opinion: Adequate proof supports the use of Cannabis for palliative indications in oncology on the other hand, sufferers need to be cautiously chosen, guided and followed. Promising investigation suggests the potent antineoplastic activity, but a lot more information have to be accrued ahead of conclusions can be drawn.